[Federal Register: October 25, 2007 (Volume 72, Number 206)]
[Rules and Regulations]
[Page 60550-60551]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25oc07-8]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs; Spinosad
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a new animal drug application
(NADA) filed by Elanco Animal Health. The NADA provides for veterinary
prescription use of spinosad chewable tablets to kill fleas and for the
prevention and treatment of flea infestations on dogs for 1 month.
DATES: This rule is effective October 25, 2007.
FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-7540, e-mail:
melanie.berson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Elanco Animal Health, A Division of Eli
Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, filed NADA
141-277 that provides for veterinary prescription use of COMFORTIS
(spinosad) Chewable Tablets to kill fleas and for the prevention and
treatment of flea infestations (Ctenocephalides felis) on dogs for 1
month. The NADA is approved as of September 25, 2007, and the
regulations in 21 CFR part 520 are amended by adding Sec. 520.2130 to
reflect the approval.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for
5 years of marketing exclusivity beginning on the date of approval.
FDA has determined under 21 CFR 25.33(d)(1) that this action is of
a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore,
[[Page 60551]]
neither an environmental assessment nor an environmental impact
statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 520
Animal drugs.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is
amended as follows:
PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: 21 U.S.C. 360b.
0
2. Add Sec. 520.2130 to read as follows:
Sec. 520.2130 Spinosad.
(a) Specifications. Each chewable tablet contains 140, 270, 560,
810, or 1620 milligrams (mg) spinosad.
(b) Sponsor. See No. 000986 in Sec. 510.600 of this chapter.
(c) Conditions of use in dogs--(1) Amount. Administer tablets once
a month at a recommended minimum dosage of 13.5 mg per pound (30 mg per
kilogram) of body weight.
(2) Indications for use. To kill fleas and for the prevention and
treatment of flea infestations (Ctenocephalides felis) on dogs for 1
month.
(3) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian.
Dated: October 17, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary Medicine.
[FR Doc. E7-21058 Filed 10-24-07; 8:45 am]
BILLING CODE 4160-01-S